Treatment of scleredema diabeticorum with tamoxifen

Journal of Rheumatology

Volumn 37, Issue 12, 2010, Pages 2636-2637

  Alsaeedi, Sabri H ^a   Lee, Peter ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DESONIDE; DICLOFENAC; DILTIAZEM; FUROSEMIDE; GLIMEPIRIDE; HYDROCHLOROTHIAZIDE; HYDROQUINONE; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; MISOPROSTOL; OXYCODONE; RAMIPRIL; RETINOIC ACID; ROSUVASTATIN; TAMOXIFEN; TRIAMTERENE;

ADULT; CASE REPORT; CHEST TIGHTNESS; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC OBESITY; DIABETIC RETINOPATHY; DRUG DOSE REDUCTION; ECHOCARDIOGRAPHY; FEMALE; FILIPINO; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL NEUROPATHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLEREDEMA; SCLEREDEMA DIABETICORUM; SKINFOLD; SLEEP APNEA SYNDROME; TENOSYNOVITIS;

ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; SCLEREDEMA ADULTORUM; TAMOXIFEN; TREATMENT OUTCOME;

EID: 78649728580     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100561     Document Type: Letter

References (17)

1. Buschke A. Ueber scleroedem. Berl Klin Wochenschr 1902;39:955-7.
2. Graff R. Discussion. Arch Dermatol 1968;98:320.
3. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med 2008;75:772-4,6,7.
4. Venencie PY, Powell FC, Su WP, Perry HO. Scleredema: a review of thirty-three cases. J Am Acad Dermatol 1984;11:128-34.
5. Buckingham B, Reiser KM. Relationship between the content of lysyl oxidase-dependent cross-links in skin collagen I non-enzymatic glycosylation and long-term complications in type I diabetes mellitus. J Clin Invest 1990;86:1046-54.
6. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, et al. Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 2001;142:1760-9. (Pubitemid 32405931)
7. Mattheou-Vakali G, Ioannides D, Thomas T, Lazaridou E, Tsogas P, Minas A. Cyclosporine in scleredema. J Am Acad Dermatol 1996;35:990-1.
8. Breuckmann F, Appelhans C, Harati A, Rotterdam S, Altmeyer P, Kreuter A. Failure of low-dose methotrexate in the treatment of scleredema diabeticorum in seven cases. Dermatology 2005;211:299-301.
9. Kroft EB, de Jong EM. Scleredema diabeticorum case series: Successful treatment with UV-A1. Arch Dermatol 2008;144:947-8.
10. Hager CM, Sobhi HA, Hunzelmann N, Wickenhauser C, Scharenberg R, Krieg T, et al. Bath-PUVA therapy in three patients with scleredema adultorum. J Am Acad Dermatol 1998;38:240-2.
11. Ikeda Y, Suehiro T, Abe T, Yoshida T, Shinoki T, Tahara K, et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin E1. Intern Med 1998;37:861-4.
12. Clark CP, Vanderpool D, Preskitt JT. The response of retroperitoneal fibrosis to tamoxifen. Surgery 1991;109:502-6.
13. Spillane RM, Whitman GJ. Treatment of retroperitoneal fibrosis with tamoxifen. AJR Am J Roentgenol 1995;164:515-6.
14. McNamara DA, Harmey J, Wang JH, Kay E, Walsh TN, Bouchier-Hayes DJ. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001;27:714-8.
15. Thomas-Golbanov CK, Wilke WS, Fessler BJ, Hoffman GS. Open label trial of tamoxifen in scleroderma. Clin Exp Rheumatol 2003;21:99-102.
16. Sarkar RN, Banerjee S, Basu AK, Bandyopadhyay D. Rheumatological manifestations of diabetes mellitus. J Indian Rheumatol Assoc 3003;11:25-9.
17. Scherbaum WA, Koubik J, Winkler G, Pfeiffer EF. Clinical and laboratory chemical studies of the incidence and extent of diabetic cheiropathy in childhood and adolescence. Medizinische Klinik 1989;15:1-4.